Discover CRI’s 2026 CLIP and Technology Impact Award projects — funding bold cancer immunotherapy research and new tools to advance treatments.

Kureshi et al. show that combining an innate immune agonist and immune checkpoint blockade effectively treats pancreatic tumors in mouse models. Tumor control depends on cDC2-primed CD4+ T cells and IFNγ. Human PDAC retains cDC2s and CD4+ T cells after chemotherapy, suggesting a potential therapeutic approach for PDAC.

Nature Biomedical Engineering, Published online: 07 July 2026; doi:10.1038/s41551-026-01738-zChemRNAs are chemically synthesized RNA lacking typical mRNA features that are nevertheless efficiently translated by CD8+ T cells to overcome limitations associated with in vitro transcription for developing anti-cancer mRNA vaccines.

Immune-remodeling mRNAs delivered in lipid nanoparticles boost antitumor immunity.

Mestrallet et al. show that T cell-myeloid interactions determine response to PD-1 blockade in colorectal cancer. Targeting TREM2 macrophages together with LAG3, CTLA4, and PD-1 reprograms the tumor m...

Abstract. Purpose Oxaliplatin has demonstrated the ability to sensitize tumors to immune checkpoint blockade through its immunomodulatory properties in model systems of cancer. This randomized trial a...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened to slow or derail dozens of potential cancer treatments. Now there are sig...

mRNA–lipid-nanoparticle vaccines do not require type 1 conventional dendritic (cDC1) cells or the WDFY4-dependent cross-presentation pathway for CD8+ T cell priming but, instead, engage both cDC1 and ...

This study presents an organ-wide spatial transcriptomic analysis of human skin from different anatomical sites using a combination of MERFISH technology and existing datasets from healthy and disease...

PEG-free, one-component Janus dendrimers deliver mRNA with high stability and strong immunity, enabling scalable vaccines.

mRNA vaccines combine rapid design, scalable manufacturing and strong safety profiles with applications across infectious diseases, cancer and autoimmune disorders. However, global access to mRNA vacc...

Proinflammatory innate immune activation by unmodified mRNA is a limitation, which mandates mRNA-nucleoside modification across applications. However, Drzeniek and colleagues reveal that it is absent ...

Evo 2 is an artificial intelligence-based biological foundation model trained on 9 trillion DNA base pairs spanning all domains of life that predicts functional properties from genomic sequences and provides a rich generative model for researchers in biology.

Surveying recent progress in neoantigen cancer vaccine development, this Review highlights areas where further technological advances and optimized trial design could enhance clinical impact.

In a prespecified ancillary analysis of the COSMOS randomized trial, supplementation with daily multivitamins, but not with cocoa extract, over the course of 2 years decreased biological aging, as mea...

Garg et al. report that blocking the molecule SEMA4D strengthens immune responses against HER2-positive breast cancer. When paired with specialized dendritic cells, this approach boosts anti-tumor imm...

T-cell receptors (TCRs) are generated through somatic recombination of variable (V), diversity (D), and joining (J) gene segments, resulting in an extraordinarily diverse receptor repertoire that is e...

11th Edition Theme: Targeting Immune Aging | Time: 9:00am-1.15pm NYC; 14:00-18.15h Paris; 10:00am-2.15pm Sao Paulo

Whether a T-cell response to dead cells arises depends on whether they harbor recognizable antigens, but also how dead cell debris impacts conventional dendritic cells (cDCs). In all tissues, cell debris is continuously phagocytosed by cDCs that can migrate to lymph nodes (LNs) and initiate T-cell r …

Messenger RNA (mRNA) vaccines in lipid nanoparticles (LNPs) are effective, yet immunity can wane, and reactogenicity increases with dose. We integrate ionizable lipid design, LNP formulation, and untr...

Elucidation of fundamental pancreatic-targeted mechanisms enables the development of lipid nanoparticles for the precise delivery of nucleic acid therapeutics to the pancreas, highlighting their promi...

In a phase 1 trial, personalized mRNA vaccines tailored to individual tumour mutations in triple-negative breast cancer induced robust, long-lasting T cell responses and improved prognosis.

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

AACR Immuno-Oncology Conference cochair Antoni Ribas, MD, PhD, discusses what makes the meeting – #AACRio26 – unique , what he's excited about in the field, and the impact of immunotherapy on…

The AACR’s immuno-oncology meeting in Los Angeles, Feb. 23-26, 2025, brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.